Melissa Johnson named program director of lung cancer research at Sarah Cannon

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Melissa Johnson was named program director of lung cancer research at Sarah Cannon.

In this role, Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.

Since joining Sarah Cannon in 2014, Johnson has served as the associate director of lung cancer research at Sarah Cannon Research Institute, supporting the growth of early phase compounds in thoracic malignancies.

Johnson will continue to work in early phase drug development as well as lead the Solid Tumor Immune Effector Cellular Therapy Program at Sarah Cannon. She is also the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville.

Johnson begins her position in January at Sarah Cannon headquarters in Nashville. She will continue to care for patients as a partner with Tennessee Oncology, PLLC.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login